ClinicalTrials.gg
RecruitingNCT07247084Updated Sep 9, 2026

A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)

A Phase 4 interventional study of Tirzepatide and Standard of Care in Obesity, sponsored by Eli Lilly and Company. Recruiting at 30 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
3,000
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 104 studies testing tirzepatide in Obesity — 60 open to participants now, 79 under way, 14 of them phase 3. Tirzepatide · Obesity.

Planned enrollment
2nd of 104
3,000 · median 69
Started
2025
with 33 others
Phase 4
29 of 104
20 open now
Primary completion
2029-07
later than 71 of 78 live
Registered
67th of 104
by date
Lead sponsor
34 of 104
Eli Lilly and Company

Among the 104 studies testing tirzepatide in Obesity, this one is the 2nd largest by planned enrollment, is one of 34 that started in 2025, is one of 29 in phase 4, reaches primary completion later than 71 of the 78 other live ones, and was the 67th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

60 of the 104 studies testing tirzepatide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

55 more — sign in →

By country, each count listing its studies:

All 60 open studies →

About tirzepatide

Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies testing tirzepatide in Obesity, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate tirzepatide within a real-world setting to assess body weight loss and incidence of type 2 diabetes in adults without diabetes who have obesity and at least one weight-related comorbid condition.

Eligible participants must be registered patients at a participating site. Participation in the study will last about 260 weeks.

03

Conditions studied

  • Obesity

Keywords

  • Overweight
  • Electronic health records
  • Primary care
  • Type 2 diabetes incidence
  • Obesity related complications
  • Pragmatic trial
  • Randomized trial
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a ≥30 and ≤34.9 kilogram per square meter (kg/m2)
  • Have an increased waist to height ratio (defined by >0.5)
  • Have at least one weight related comorbid condition
  • Have had at least one attempt to lose weight with lifestyle intervention (diet and physical activity)

Exclusion criteria

Exclusion Criteria:

  • Have type 1 diabetes, type 2 diabetes, or any other types of diabetes
  • Have had a change in body weight of greater than 5 kilograms (11 pounds) within 90 days prior to screening
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
3,000 participants (estimated)

Study arms

  • Experimental
    Tirzepatide + Standard of Care

    Participants will receive tirzepatide subcutaneously (SC) + standard of care

    Drug: Tirzepatide

  • Active comparator
    Standard of Care

    Other: Standard of Care

Interventions

  • Administered SC

    Also known as: LY3298176

  • OtherStandard of Care

    Standard of care

06

What researchers measure

Primary outcomes

  1. Percent Change from Baseline in Body Weight

    Time frame: Baseline, 24 months

Secondary outcomes

  1. Time from Baseline to Onset of Type 2 Diabetes

    Time frame: Baseline through 60 months

  2. Percentage of Participants Converting from Prediabetes to Normoglycemia

    Time frame: 60 months

  3. Percentage of Participants with Normoglycemia at Baseline who Develop Prediabetes

    Time frame: 60 months

  4. Change from Baseline in Hemoglobin A1c (HbA1c)

    Time frame: Baseline, 60 months

  5. Percentage of Participants who Develop a New Obesity-Related Complication

    Time frame: 60 months

  6. Change from Baseline in Waist Circumference

    Time frame: Baseline, 60 months

  7. Change from Baseline in Waist-to-Height Ratio

    Time frame: Baseline, 60 months

  8. Change from Baseline in Total Cholesterol

    Time frame: Baseline, 60 months

  9. Change from Baseline in Systolic Blood Pressure

    Time frame: Baseline, 60 months

  10. Change from Baseline in Diastolic Blood Pressure

    Time frame: Baseline, 60 months

  11. Percent Change from Baseline Urinary Albumin-to-Creatinine Ratio (UACR)

    Time frame: Baseline, 60 months

  12. Change from Baseline in EQ-5D-5L

    Time frame: Baseline, 60 months

  13. Change from Baseline in Impact of Weight on Quality of Life-Lite-Clinical Trials (IWQOL-lite-CT)

    Time frame: Baseline, 60 months

  14. Change from Baseline in Healthcare Resource Utilization (HCRU)

    Time frame: Baseline, 60 months

  15. Change from Baseline in Alanine Aminotransferase (ALT)

    Time frame: Baseline, 60 months

  16. Change from Baseline in Aspartate Aminotransferase (AST)

    Time frame: Baseline, 60 months

07

Study locations

12 of 30 sites recruiting
  • P91604 St John's Medical Centre
    Altrincham, WA14 1PF, United Kingdom
    Not yet recruiting
  • P89008 Ashton Medical Group
    Ashton-under-Lyne, OL6 6EW, United Kingdom
    Recruiting
  • Y02319 SSP Bolton General Practice
    Bolton, BL1 4TH, United Kingdom
    Not yet recruiting
  • P83012 Tower Family Healthcare
    Bury, BL9 0NJ, United Kingdom
    Not yet recruiting
  • P91014 Washway Road Medical Centre
    Cheshire, M33 7SS, United Kingdom
    Not yet recruiting
  • P88007 Cheadle Hulme Medical Group (was Cheadle Hulme Health Centre) (Bridge House)
    Cheshire, SK8 5LL, United Kingdom
    Not yet recruiting
  • Y02790 SSP Bolton Medical Centre
    Great Lever, BL3 6PY, United Kingdom
    Not yet recruiting
  • P89002 The Brooke Surgery
    Hyde SK14, SK14 1AT, United Kingdom
    Recruiting
  • P84035 Bodey Medical Centre
    Manchester, M14 6WP, United Kingdom
    Recruiting
  • P84630 The Arch Medical Practice
    Manchester, M15 5TJ, United Kingdom
    Recruiting
  • P84678 Didsbury Medical Centre
    Manchester, M20 2ER, United Kingdom
    Not yet recruiting
  • P84017 Ladybarn Group Practice
    Manchester, M20 4SS, United Kingdom
    Not yet recruiting
  • P84068 Chorlton Family Practice
    Manchester, M21 9NJ, United Kingdom
    Not yet recruiting
  • P84012 Northenden Group Practice
    Manchester, M22 4DH, United Kingdom
    Not yet recruiting
  • P86004 Peterloo Medical Centre
    Manchester, M24 4DZ, United Kingdom
    Recruiting
  • P83025 St Gabriels Medical Centre
    Manchester, M25 0HT, United Kingdom
    Not yet recruiting
  • P87019 Silverdale Medical Practice
    Manchester, M27 8 HP, United Kingdom
    Recruiting
  • P91006 Urmston Group Practice
    Manchester, M41 8AA, United Kingdom
    Not yet recruiting
  • P92620 SSP Ince Surgery (Lower Ince)
    Manchester, WN3 4NW, United Kingdom
    Not yet recruiting
  • P84034 Barlow Medical Centre
    Manchester, United Kingdom
    Not yet recruiting
  • P85010 Woodlands Medical Practice
    Oldham, OL9 0LH, United Kingdom
    Recruiting
  • P85011 CH Medical Practice
    Oldham, OL9 8NH, United Kingdom
    Recruiting
  • P86022 Stonefield Street Surgery
    Rochdale, OL16 4JF, United Kingdom
    Recruiting
  • P91021 Firsway Health Centre
    Sale, M33 4BR, United Kingdom
    Not yet recruiting
  • P91013 Boundary House Medical Centre
    Sale, United Kingdom
    Not yet recruiting
  • P87027 Langworthy Medical Practice
    Salford, M6 5WW, United Kingdom
    Recruiting
  • P88632 Stockport Medical Group
    Stockport, SK3 9NX, United Kingdom
    Not yet recruiting
  • P87016 The Sides Medical Centre
    Swinton, M27 0EW, United Kingdom
    Recruiting
  • P87025 The Lakes Medical Practice
    Swinton, M27 4AF, United Kingdom
    Recruiting
  • Y02322 SSP Leigh Family Practice
    Wigen, WN7 2PE, United Kingdom
    Not yet recruiting
08

References and documents

Publications

  • Rutter MK, Mount J, Gibson JM, Webb J, Marler C, Reed C, Gore M, Ye W, Gomez Valderas E, Wilding J, Sattar N, Davies MJ, Khunti K, Haynes R, Batterham RL. SURMOUNT-REAL UK: A Pragmatic Randomized Clinical Trial to Assess the Effectiveness of Tirzepatide in Adults With Obesity. Obesity (Silver Spring). 2026 Jun 15. doi: 10.1002/oby.70247. Online ahead of print. PubMed 42297568 ↗

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Jul 2029, 44 months after the start.

Of 210 phase 4 interventional studies under Obesity, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 44 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2025
First posted
Nov 25, 2025
StartActual
Nov 24, 2025
Primary completionEst.
Jul 2029
CompletionEst.
Jul 2032
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07247084
Responsible party
Sponsor
First posted
Nov 25, 2025
Start date
Nov 24, 2025
Primary completion
Jul 2029 (estimated)
Completion
Jul 2032 (estimated)
Last update
Sep 9, 2026

Study contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Contact
LillyTrials@Lilly.com
317-615-4559
Physicians interested in becoming principal investigators please contact
Contact
clinical_inquiry_hub@lilly.com
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion